LQCL2304 - CMLE - THERAPEUTIC DRUG MONITORING OF MONOCLONAL ANTIBODY THERAPIES IN INFLAMMATORY BOWEL DISEASE-THERAPEUTIC DRUG MONITORING OF MONOCLONAL ANTIBODY THERAPIES IN INFLAMMATORY BOWEL DISEASE

THERAPEUTIC DRUG MONITORING OF MONOCLONAL ANTIBODY THERAPIES IN INFLAMMATORY BOWEL DISEASE

Pdf Summary

The document provides insights into therapeutic drug monitoring (TDM) of monoclonal antibody therapies in inflammatory bowel disease (IBD), focusing on the case of a patient with Crohn disease who experienced an adverse reaction to infliximab treatment. It discusses the significance of TDM in identifying ineffective drug therapy or disease worsening, emphasizing the role of the clinical laboratory in developing assays for patient management. Various scenarios in which TDM is utilized and the importance of monitoring monoclonal antibody therapies are highlighted. <br /><br />Monoclonal antibodies play a crucial role in treating IBD, with therapies targeting tumor necrosis factor (TNF) and other inflammatory molecules. The text outlines approved monoclonal antibodies for IBD treatment, their mechanisms of action, and differences from small-molecule drugs. It further delves into the metabolism, immunogenicity, and half-life of monoclonal antibodies, explaining the implications of antidrug antibodies (ADAs) in therapy response.<br /><br />Moreover, the document details TDM protocols for IBD treatment, distinguishing between reactive and proactive monitoring approaches. It discusses the laboratory methods for measuring monoclonal antibody concentrations and ADAs, emphasizing the clinical significance of neutralizing ADAs in affecting drug clearance. A case study exemplifies the application of TDM in adjusting therapy based on drug concentrations and ADAs, ensuring optimal treatment outcomes for the patient. <br /><br />The summary highlights the pivotal role of TDM in managing patients with IBD, with new evidence supporting proactive monitoring to enhance therapy outcomes. It underscores the importance of accurate laboratory assays in guiding treatment decisions, demonstrating the evolution and impact of monoclonal antibody therapies in IBD management.

Keywords

Therapeutic drug monitoring

Monoclonal antibody therapies

Inflammatory bowel disease

Crohn disease

Infliximab treatment

Tumor necrosis factor

Antidrug antibodies

Reactive monitoring

Proactive monitoring

Clinical laboratory assays